Literature DB >> 7609053

The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells.

N M Clark1, M C Hannibal, D M Markovitz.   

Abstract

Human immunodeficiency virus type 2 (HIV-2), like HIV-1, causes AIDS and is associated with AIDS cases primarily in West Africa. HIV-1 and HIV-2 display significant differences in nucleic acid sequence and in the natural history of clinical disease. Consistent with these differences, we have previously demonstrated that the enhancer/promoter region of HIV-2 functions quite differently from that of HIV-1. Whereas activation of the HIV-1 enhancer following T-cell stimulation is mediated largely through binding of the transcription factor NF-kappa B to two adjacent kappa B sites in the HIV-1 long terminal repeat, activation of the HIV-2 enhancer in monocytes and T cells is dependent on four cis-acting elements: a single kappa B site, two purine-rich binding sites, PuB1 and PuB2, and a pets site. We have now identified a novel cis-acting element within the HIV-2 enhancer, immediately upstream of the kappa B site, designated peri-kappa B. This site is conserved among isolates of HIV-2 and the closely related simian immunodeficiency virus, and transfection assays show this site to mediate HIV-2 enhancer activation following stimulation of monocytic but not T-cell lines. This is the first description of an HIV-2 enhancer element which displays such monocyte specificity, and no comparable enhancer element has been clearly defined for HIV-1. While a nuclear factor(s) from both peripheral blood monocytes and T cells binds the peri-kappa B site, electrophoretic mobility shift assays suggest that either a different protein binds to this site in monocytes versus T cells or that the protein recognizing this enhancer element undergoes differential modification in monocytes and T cells, thus supporting the transfection data. Further, while specific constitutive binding to the peri-kappa B site is seen in monocytes, stimulation with phorbol esters induces additional, specific binding. Understanding the monocyte-specific function of the peri-kappa B factor may ultimately provide insight into the different role monocytes and T cells play in HIV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609053      PMCID: PMC189299          DOI: 10.1128/JVI.69.8.4854-4862.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1.

Authors:  D M Markovitz; M C Hannibal; M J Smith; R Cossman; G J Nabel
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1.

Authors:  C B Thompson; C Y Wang; I C Ho; P R Bohjanen; B Petryniak; C H June; S Miesfeldt; L Zhang; G J Nabel; B Karpinski
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

Review 3.  Mechanisms of HIV-1 latency.

Authors:  D P Bednarik; T M Folks
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

4.  Human infection by genetically diverse SIVSM-related HIV-2 in west Africa.

Authors:  F Gao; L Yue; A T White; P G Pappas; J Barchue; A P Hanson; B M Greene; P M Sharp; G M Shaw; B H Hahn
Journal:  Nature       Date:  1992-08-06       Impact factor: 49.962

5.  The hLEF/TCF-1 alpha HMG protein contains a context-dependent transcriptional activation domain that induces the TCR alpha enhancer in T cells.

Authors:  P Carlsson; M L Waterman; K A Jones
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

6.  Activation of the human T-cell leukemia virus type I enhancer is mediated by binding sites for Elf-1 and the pets factor.

Authors:  N M Clark; M J Smith; J M Hilfinger; D M Markovitz
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Differential role of long terminal repeat control elements for the regulation of basal and Tat-mediated transcription of the human immunodeficiency virus in stimulated and unstimulated primary human macrophages.

Authors:  A V Moses; C Ibanez; R Gaynor; P Ghazal; J A Nelson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

Authors:  K M De Cock; G Adjorlolo; E Ekpini; T Sibailly; J Kouadio; M Maran; K Brattegaard; K M Vetter; R Doorly; H D Gayle
Journal:  JAMA       Date:  1993-11-03       Impact factor: 56.272

9.  Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements.

Authors:  D M Markovitz; M J Smith; J Hilfinger; M C Hannibal; B Petryniak; G J Nabel
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Evolutionarily conserved Ets family members display distinct DNA binding specificities.

Authors:  C Y Wang; B Petryniak; I C Ho; C B Thompson; J M Leiden
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

View more
  9 in total

1.  The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation.

Authors:  C Browning; J M Hilfinger; S Rainier; V Lin; S Hedderwick; M Smith; D M Markovitz
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Induction of AIDS by simian immunodeficiency virus lacking NF-kappaB and SP1 binding elements.

Authors:  P O Ilyinskii; M A Simon; S C Czajak; A A Lackner; R C Desrosiers
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.

Authors:  A G Bassuk; R T Anandappa; J M Leiden
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo.

Authors:  S J Popper; A D Sarr; A Guèye-Ndiaye; S Mboup; M E Essex; P J Kanki
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  The nfkb1 promoter is controlled by proteins of the Ets family.

Authors:  P F Lambert; M J Ludford-Menting; N J Deacon; I Kola; R R Doherty
Journal:  Mol Biol Cell       Date:  1997-02       Impact factor: 4.138

6.  Sequences just upstream of the simian immunodeficiency virus core enhancer allow efficient replication in the absence of NF-kappaB and Sp1 binding elements.

Authors:  S Pöhlmann; S Flöss; P O Ilyinskii; T Stamminger; F Kirchhoff
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  GLI-2 modulates retroviral gene expression.

Authors:  M J Smith; S D Gitlin; C M Browning; B R Lane; N M Clark; N Shah; S Rainier; D M Markovitz
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements.

Authors:  P O Ilyinskii; R C Desrosiers
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 9.  HIV-2 as a model to identify a functional HIV cure.

Authors:  Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse
Journal:  AIDS Res Ther       Date:  2019-09-05       Impact factor: 2.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.